Insmed INC Form 4 insider transactions

INSMED's Chief Medical Officer, Martina M.D. Flammer, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

INSMED Inc. Director Elizabeth M. Anderson reported the sale of 5,000 shares of common stock for $204.58 per share, executed under a Rule 10b5-1 trading plan.

INSMED Inc. Director Leo Lee executed sales of 75,000 shares of common stock on November 17, 2025, under a Rule 10b5-1 plan.

An Insmed Inc. director has filed a Form 4 indicating a future sale of 10,000 shares of common stock at $195.87 per share under a pre-arranged trading plan.

INSMED's Chief People Strategy Officer, S. Nicole Schaeffer, exercised stock options and subsequently sold a significant portion of common stock under a pre-arranged plan.

INSMED's Chief Medical Officer, Martina M.D. Flammer, exercised stock options and subsequently sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

INSMED Director David R. Brennan reported gifting 60,000 shares of common stock to a spouse revocable trust, maintaining indirect beneficial ownership.

INSMED's Chief Legal Officer, Michael Alexander Smith, exercised stock options and subsequently sold 27,130 shares of common stock on November 3, 2025, under a pre-arranged 10b5-1 trading plan.

INSMED's Chief People Strategy Officer, S. Nicole Schaeffer, exercised stock options and subsequently sold a significant number of common shares on September 12, 2025, under a pre-arranged 10b5-1 trading plan.

INSMED Director Melvin Sharoky, MD, reported the sale of 10,000 common shares for $145.39 each and several gift transactions under a 10b5-1 plan.

INSMED's Chief People Strategy Officer, S. Nicole Schaeffer, reported a planned future gift of 23,303 shares of common stock effective September 4, 2025.

INSMED's Chief Legal Officer, Michael Alexander Smith, exercised stock options and subsequently sold a significant number of common shares under a pre-arranged 10b5-1 trading plan.

INSMED's Chief Medical Officer, Martina Flammer, exercised stock options and simultaneously sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.

INSMED Inc. Director Melvin Sharoky, M.D., reported the sale of 10,000 shares of common stock for $129.5 per share, effective August 20, 2025, under a Rule 10b5-1 plan.

INSMED Inc.'s Chief Operating Officer, Roger Adsett, sold 25,000 shares of common stock for approximately $3.2 million through a pre-arranged 10b5-1 plan.

INSMED Inc. CEO William Lewis exercised stock options and subsequently sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

INSMED's Chief People Strategy Officer, S. Nicole Schaeffer, sold 10,000 shares of common stock for approximately $1.27 million under a pre-arranged trading plan.

INSMED Director Melvin Sharoky reported the sale of 10,000 shares and gifts of 26,100 shares, adjusting his beneficial ownership.

INSMED Inc.'s CEO, William Lewis, exercised stock options and simultaneously sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

INSMED's Chief Medical Officer, Martina Flammer, executed a pre-planned transaction, exercising stock options and simultaneously selling shares.

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, engaged in pre-scheduled transactions, exercising stock options and subsequently selling shares under a Rule 10b5-1 trading plan.

INSMED Inc.'s Chair and CEO, William Lewis, acquired 6,830 shares through option exercise and subsequently sold 6,830 shares at prices ranging from $101.10 to $103.37, all pursuant to a Rule 10b5-1 trading plan.

INSMED Inc.'s Chief Legal Officer, Michael Alexander Smith, reported two separate sales of common stock totaling 1,681 shares in July 2025, primarily to cover tax withholding and pursuant to a Rule 10b5-1 trading plan.

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, executed pre-planned transactions on July 7, 2025, involving the exercise of stock options and subsequent sale of common stock under a Rule 10b5-1 trading plan.

INSMED Inc.'s Chair and CEO, William Lewis, reported the exercise of stock options and subsequent sales of common stock through a pre-arranged 10b5-1 trading plan.

INSMED Inc.'s Chief Financial Officer, Sara Bonstein, executed a series of transactions on June 23, 2025, exercising stock options at low prices and subsequently selling a portion of the acquired shares at significantly higher market prices under a Rule 10b5-1 trading plan.

INSMED Inc.'s Chair and CEO, William Lewis, reported the direct sale of 5,204 shares of common stock and the exercise and immediate sale of 129,805 shares by a family trust, all conducted under a pre-arranged 10b5-1 trading plan.

INSMED Inc.'s Chief Operating Officer, Roger Adsett, sold 10,686 shares of common stock in two transactions on June 16, 2025, as part of a pre-established Rule 10b5-1 trading plan.

INSMED Inc.'s Chief People Strategy Officer, S. Nicole Schaeffer, executed significant stock option exercises and subsequent share sales totaling over 100,000 shares in early June 2025, all conducted under pre-established 10b5-1 trading plans.

INSMED Inc.'s Chief Medical Officer, Martina M.D. Flammer, executed a series of stock option exercises and subsequent share sales totaling over $4.1 million in proceeds, as part of a pre-established 10b5-1 trading plan.